Abstract
Key content The use and pharmacokinetics of retinoids. The main known teratogenic effects of retinoids are face, skull, cardiovascular, nervous system and thymic abnormalities. The pregnancy prevention programme must be adhered to when initiating retinoid treatment. Effective contraception should be continued for at least one month after cessation of retinoid treatment. Management options of pregnant women with recent retinoid use or exposure in early pregnancy; including involvement of the specialist multidisciplinary team. Learning objectives To understand the risk and in particular teratogenesis associated with exposure to retinoids peri‐conception. To raise awareness of the pregnancy prevention programme. To highlight the management options for women who become pregnant with recent retinoid use or exposure in early pregnancy. Ethical issues Termination of pregnancy with peri‐conceptual exposure to retinoids. Should isotretinoin be used so widely in the childbearing population when we are aware of its teratogenicity?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
